MAPK3 and B-cell chronic lymphocytic leukemia: However, contrary to what we observed when cells were only stimulated by anti-IgM, the phosphorylation of ERK1/2 was not inhibited by TAK-659 treatment, reflecting persistent activation of alternative pathways independent from Syk in co-cultured primary CLL cells (Figure 2E and 2F).